Cerus Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Cerus wird ein Gewinn- und Umsatzwachstum von 47.5% bzw. 10.7% pro Jahr prognostiziert, während der Gewinn pro Aktie um 48.9% pro Jahr wachsen soll.

Wichtige Informationen

47.5%

Wachstumsrate der Gewinne

48.9%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	10.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	31 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Analysts Are Upgrading Cerus Corporation (NASDAQ:CERS) After Its Latest Results

Aug 04

The Cerus Corporation (NASDAQ:CERS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 05

Recent updates

Cerus Corporation (NASDAQ:CERS) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Sep 26

The Cerus Corporation (NASDAQ:CERS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 05

Here's Why Cerus (NASDAQ:CERS) Can Afford Some Debt

Apr 12

Cerus Corporation (NASDAQ:CERS) Stock Rockets 29% But Many Are Still Ignoring The Company

Mar 07

Slammed 29% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch

Jan 18

Health Check: How Prudently Does Cerus (NASDAQ:CERS) Use Debt?

Oct 06

Is Cerus (NASDAQ:CERS) A Risky Investment?

Jul 07

Slammed 32% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch

May 12

Cerus: Technical Support Fades, Investment Case Weakens (Technical Analysis)

Sep 29

Cerus GAAP EPS of -$0.05 beats by $0.02, revenue of $47.63M beats by $4.87M

Aug 04

Cerus: Lacks Conviction Against Macro Backdrop, Technicals Supportive Of Near-Term Upside

Jul 14

Is Cerus (NASDAQ:CERS) Using Debt In A Risky Way?

Jul 06

Is Cerus (NASDAQ:CERS) Using Debt Sensibly?

Mar 17

Cerus Corporation: Outperforming And Gaining Momentum

Jan 28

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:CERS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	225	-4	N/A	N/A	4
12/31/2025	206	-14	N/A	N/A	5
12/31/2024	186	-21	N/A	N/A	5
9/30/2024	176	-20	-11	-9	N/A
6/30/2024	170	-24	-27	-23	N/A
3/31/2024	164	-32	-37	-33	N/A
12/31/2023	156	-37	-48	-43	N/A
9/30/2023	154	-50	-36	-30	N/A
6/30/2023	153	-51	-25	-21	N/A
3/31/2023	156	-46	-16	-13	N/A
12/31/2022	162	-43	-28	-26	N/A
9/30/2022	158	-38	-26	-25	N/A
6/30/2022	154	-42	-30	-30	N/A
3/31/2022	145	-49	-39	-38	N/A
12/31/2021	131	-54	-35	-34	N/A
9/30/2021	119	-60	-43	-42	N/A
6/30/2021	107	-61	-41	-40	N/A
3/31/2021	97	-61	-41	-39	N/A
12/31/2020	92	-60	-43	-42	N/A
9/30/2020	85	-62	-43	-41	N/A
6/30/2020	79	-66	-62	-58	N/A
3/31/2020	76	-69	-70	-63	N/A
12/31/2019	75	-71	-74	-65	N/A
9/30/2019	70	-71	-73	-64	N/A
6/30/2019	68	-67	-55	-47	N/A
3/31/2019	65	-62	-48	-43	N/A
12/31/2018	61	-58	-32	-31	N/A
9/30/2018	61	-53	-35	-34	N/A
6/30/2018	56	-52	N/A	-42	N/A
3/31/2018	50	-56	N/A	-46	N/A
12/31/2017	44	-61	N/A	-52	N/A
9/30/2017	37	-63	N/A	-52	N/A
6/30/2017	37	-64	N/A	-55	N/A
3/31/2017	37	-65	N/A	-57	N/A
12/31/2016	37	-63	N/A	-54	N/A
9/30/2016	37	-64	N/A	-53	N/A
6/30/2016	35	-65	N/A	-48	N/A
3/31/2016	34	-63	N/A	-48	N/A
12/31/2015	34	-56	N/A	-51	N/A
9/30/2015	34	-61	N/A	-51	N/A
6/30/2015	36	-56	N/A	-51	N/A
3/31/2015	36	-48	N/A	-46	N/A
12/31/2014	36	-39	N/A	-40	N/A
9/30/2014	36	-24	N/A	-38	N/A
6/30/2014	36	-34	N/A	-32	N/A
3/31/2014	38	-33	N/A	-28	N/A
12/31/2013	40	-43	N/A	-27	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CERS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CERS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CERS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CERSDie Einnahmen des Unternehmens (10.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: CERSDie Einnahmen des Unternehmens (10.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CERS in 3 Jahren voraussichtlich hoch sein wird

Cerus Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Analysts Are Upgrading Cerus Corporation (NASDAQ:CERS) After Its Latest Results

Consensus EPS estimates fall by 29%

The Cerus Corporation (NASDAQ:CERS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Cerus Corporation Reiterates Earnings Guidance for the Year Ending December 31, 2024

Consensus EPS estimates fall by 24%, revenue upgraded

Consensus EPS estimates upgraded to US$0.085 loss, revenue downgraded

Recent updates

Cerus Corporation to Report Q3, 2024 Results on Oct 30, 2024

Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe

Cerus Corporation (NASDAQ:CERS) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Analysts Are Upgrading Cerus Corporation (NASDAQ:CERS) After Its Latest Results

Cerus Corporation's (NASDAQ:CERS) 30% Jump Shows Its Popularity With Investors

Cerus Corporation to Report Q2, 2024 Results on Aug 01, 2024

Does Cerus (NASDAQ:CERS) Have A Healthy Balance Sheet?

Cerus Corporation Appoints Dean Gregory to its Board of Directors

Consensus EPS estimates fall by 29%

The Cerus Corporation (NASDAQ:CERS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

First quarter 2024 earnings: EPS misses analyst expectations

Cerus Corporation Reiterates Earnings Guidance for the Year Ending December 31, 2024

Cerus Corporation, Annual General Meeting, Jun 05, 2024

Cerus Corporation to Report Q1, 2024 Results on May 02, 2024

Here's Why Cerus (NASDAQ:CERS) Can Afford Some Debt

Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets - Doubling Previous Shelf Life

Consensus EPS estimates fall by 24%, revenue upgraded

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

Consensus EPS estimates upgraded to US$0.085 loss, revenue downgraded

Chief Medical Officer notifies of intention to sell stock

No longer forecast to breakeven

Cerus Corporation (NASDAQ:CERS) Stock Rockets 29% But Many Are Still Ignoring The Company

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cerus Corporation Reiterates Product Revenue Guidance for the Full Year 2024

Cerus Corporation to Report Fiscal Year 2023 Results on Mar 05, 2024

Forecast to breakeven in 2025

Slammed 29% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch

Cerus Corporation Provides Revenue Guidance for the Fiscal Year 2024

Price target decreased by 28% to US$4.13

Cerus Corporation has filed a Follow-on Equity Offering in the amount of $96.8 million.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cerus Corporation Provides Product Revenue Guidance for the Full-Year 2023

Cerus Corporation to Report Q3, 2023 Results on Nov 02, 2023

Health Check: How Prudently Does Cerus (NASDAQ:CERS) Use Debt?

Cerus Corporation Announces the Appointment of Alicia Goodman as Chief Human Resources Officer

Price target decreased by 25% to US$5.75

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Cerus Corporation Revises Revenue Guidance for the Year 2023

New minor risk - Share price stability

Is Cerus (NASDAQ:CERS) A Risky Investment?

Slammed 32% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch

Consensus EPS estimates fall by 12%

No longer forecast to breakeven

Cerus Corporation Reiterates Revenue Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Medical Officer exercised options and sold US$71k worth of stock

No longer forecast to breakeven

Cerus Corporation to Report Q4, 2022 Results on Feb 28, 2023

No longer forecast to breakeven

Cerus Corporation Provides Revenue Guidance for the Full Year 2023

Independent Director exercised options to buy US$94k worth of stock.

Price target decreased to US$8.70

No longer forecast to breakeven

Price target decreased to US$8.70

Consensus estimates of losses per share improve by 13%

Price target decreased to US$8.50

Third quarter 2022 earnings released: US$0.048 loss per share (vs US$0.072 loss in 3Q 2021)

Cerus Corporation Revises Revenue Guidance for Full Year 2022

Price target decreased to US$8.50

Cerus Corporation Announces Health Canada Approval for Intercept Blood System for Platelets with Seven-Day Storage

Cerus Corporation to Report Q3, 2022 Results on Nov 03, 2022

Cerus: Technical Support Fades, Investment Case Weakens (Technical Analysis)

Chief Medical Officer notifies of intention to sell stock

Consensus forecasts updated

No longer forecast to breakeven

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cerus Corporation Reiterates Revenue Guidance for the Full Year 2022

Cerus GAAP EPS of -$0.05 beats by $0.02, revenue of $47.63M beats by $4.87M